Keratitis: Difference between revisions

Jump to navigation Jump to search
Line 49: Line 49:
{|style="width:80%; height:100px" border="1"
{|style="width:80%; height:100px" border="1"
|style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular'''
|style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular'''
|style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | No underlying causes
|style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | [[Amaurosis fugax]], [[rheumatoid vasculitis]], [[vasculitis]]
|-
|-
|bgcolor="LightSteelBlue"| '''Chemical/Poisoning'''
|bgcolor="LightSteelBlue"| '''Chemical/Poisoning'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"| [[water pollution|Contaminated water]], [[jellyfish|jellyfish stings]], [[phosgene oxime]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
Line 60: Line 60:
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Dermatologic'''
| '''Dermatologic'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"| [[Atopic dermatitis]], [[Behcet disease]], [[epidermolysis bullosa]], [[erythema elevatum diutinum]], [[erythema multiforme]], [[ichthyosis]], [[keratitis-ichthyosis-deafness syndrome]], [[KID syndrome]], [[lepromatous leprosy]], [[phycomycosis]], [[pityriasis rubra pilaris]], [[rheumatoid vasculitis]], [[Stevens-Johnson syndrome]], [[systemic lupus erythematosus]], [[toxic epidermal necrolysis]], [[vasculitis]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Drug Side Effect'''
| '''Drug Side Effect'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"| [[Aciclovir]], [[afatinib]], [[betaxolol (ophthalmic)]], [[bimatoprost]], [[brimonidine (ophthalmic)]], [[bromfenac]], [[cyclopentolate]], [[diclofenac (ophthalmic)]], [[dorzolamide]], [[doxorubicin hydrochloride]], [[Emedastine Difumarate|emedastine difumarate]], [[epinastine]], [[hydroxypropyl cellulose]], [[latanoprost]], [[moxifloxacin ophthalmic]], [[naphazoline]], [[natamycin]], [[nepafenac]], [[nitisinone]], [[non-steroidal anti-inflammatory drug|non-steroidal anti-inflammatory drug (topical)]], [[olopatadine]], [[panitumumab]], [[pramipexole]], [[scopolamine]], [[topical anesthetic]], [[travoprost]], [[trifluridine]], [[unoprostone]], [[vidarabine]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Ear Nose Throat'''
| '''Ear Nose Throat'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"| [[Cogan syndrome]], [[ectrodactyly-ectodermal dysplasia-cleft syndrome]], [[keratitis-ichthyosis-deafness syndrome]], [[KID syndrome]], [[oculovestibuloauditory syndrome]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Endocrine'''
| '''Endocrine'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"| [[Graves' disease]], [[Graves ophthalmopathy]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Environmental'''
| '''Environmental'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"| [[water pollution|Contaminated water]], [[ultraviolet radiation]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Gastroenterologic'''
| '''Gastroenterologic'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"|[[Phycomycosis]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Genetic'''
| '''Genetic'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"| [[Epidermolysis bullosa]], [[facioscapulohumeral muscular dystrophy]], [[ichthyosis]], [[incontinentia pigmenti]], [[xeroderma pigmentosum]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Hematologic'''
| '''Hematologic'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"|[[Henoch-Schönlein purpura]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Iatrogenic'''
| '''Iatrogenic'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"|[[Radial keratotomy]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Infectious Disease'''
| '''Infectious Disease'''
|bgcolor="Beige"| No underlying causes
|bgcolor="Beige"| [[Acanthamoeba]], [[adenovirus]], [[aspergillus fumigatus]], [[bacillus cereus]], [[balamuthia mandrillaris]], [[brucellosis]], [[candida]], [[canine herpesvirus]], [[congenital syphilis]], [[conjunctivitis]], [[corynebacterium diphtheriae]], [[crab louse]], [[dendritic ulcer]], [[enterobacteria]], [[enterovirus]], [[feline viral rhinotracheitis]], [[fungal keratitis]], [[fusarium]], [[haemophilus influenzae]], [[Herpes Simplex Keratitis|herpes simplex keratitis]], [[herpes simplex virus infection]], [[herpes zoster]], [[herpesviridae]], [[herpetic keratitis]], [[late congenital syphilitic oculopathy]], [[lepromatous leprosy]], [[listeria]], [[Lyme disease]], [[mansonella ozzardi]], [[measles]], [[microsporidiosis]], [[moraxella]], [[mycobacterium boenickei]], [[mycobacterium brisbanense]], [[mycobacterium houstonense]], [[mycobacterium neworleansense]], [[mycobacterium]], [[naegleria infection]], [[neisseria gonorrhea]], [[nocardiosis]], [[onchocerciasis]], [[orthopoxvirus]], [[parechovirus]], [[plesiomonas shigelloides]], [[pseudomonas aeruginosa]], [[psittacosis]], [[scedosporium apiospermum]], [[serratia marcescens]], [[shigella]], [[smallpox]], [[staphylococcus aureus]], [[staphylococcus epidermidis]], [[streptococcus pneumoniae]], [[syphilis]], [[trachoma]], [[vaccinia]], [[varicella-zoster virus]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"

Revision as of 01:50, 23 November 2015

Template:DiseaseDisorder infobox Template:Search infobox Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2], Faizan Sheraz, M.D. [3]

Overview

Keratitis is a condition in which the eye's cornea is inflamed. Superficial keratitis involves the superficial layers of the cornea. After healing, this form of keratitis does not generally leave a scar. Deep keratitis involves the deeper layers of the cornea, leaving a scar upon healing that impairs vision if on or near the visual axis. Keratitis has multiple causes, one of which is an infection of a present or previous herpes simplex virus secondary to an upper respiratory infection, involving cold sores. Symptoms of keratitis include red eyes, sensitivity to light, and uncomfortable eyes. In the later stages of more severe cases, there can be strong pain, loss of vision, blurry vision, and pus. Microbial keratitis should be managed as bacterial keratitis until proven otherwise. Steroids are indicated in the management of keratitis to reduce inflammation that may damage the eye.

Classification

Superficial keratitis involves the superficial layers of the cornea. After healing, this form of keratitis does not generally leave a scar.

Deep keratitis involves deeper layers of the cornea, leaving a scar upon healing that impairs vision if on or near the visual axis.

Pathophysiology

Keratitis has multiple causes, one of which is an infection of a present or previous herpes simplex virus secondary to an upper respiratory infection, involving cold sores.

Pathogens

  • Amoebic keratitis. Amoebic infection of the cornea is the most serious corneal infection, usually affecting soft contact lens wearers. It is usually caused by Acanthamoeba. On May 25, 2007, the CDC issued a health advisory due to increased risk of Acanthamoeba keratitis (AK)infection associated with use of Advanced Medical Optics (AMO) Complete Moisture Plus Multi-Purpose eye solution. See CDC Advisory
  • Bacterial keratitis. Bacterial infection of the cornea can follow from an injury or from wearing contact lenses. The bacteriums usually involved are Staphylococcus aureus and for contact lens wearers Pseudomonas aeruginosa.
  • Fungal keratitis (cf. Fusarium, causing recent incidences of keratitis through the possible vector of Bausch & Lomb ReNu with MoistureLoc contact lens solution)
  • Viral keratitis

Other

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Causes by Organ System

Cardiovascular Amaurosis fugax, rheumatoid vasculitis, vasculitis
Chemical/Poisoning Contaminated water, jellyfish stings, phosgene oxime
Dental No underlying causes
Dermatologic Atopic dermatitis, Behcet disease, epidermolysis bullosa, erythema elevatum diutinum, erythema multiforme, ichthyosis, keratitis-ichthyosis-deafness syndrome, KID syndrome, lepromatous leprosy, phycomycosis, pityriasis rubra pilaris, rheumatoid vasculitis, Stevens-Johnson syndrome, systemic lupus erythematosus, toxic epidermal necrolysis, vasculitis
Drug Side Effect Aciclovir, afatinib, betaxolol (ophthalmic), bimatoprost, brimonidine (ophthalmic), bromfenac, cyclopentolate, diclofenac (ophthalmic), dorzolamide, doxorubicin hydrochloride, emedastine difumarate, epinastine, hydroxypropyl cellulose, latanoprost, moxifloxacin ophthalmic, naphazoline, natamycin, nepafenac, nitisinone, non-steroidal anti-inflammatory drug (topical), olopatadine, panitumumab, pramipexole, scopolamine, topical anesthetic, travoprost, trifluridine, unoprostone, vidarabine
Ear Nose Throat Cogan syndrome, ectrodactyly-ectodermal dysplasia-cleft syndrome, keratitis-ichthyosis-deafness syndrome, KID syndrome, oculovestibuloauditory syndrome
Endocrine Graves' disease, Graves ophthalmopathy
Environmental Contaminated water, ultraviolet radiation
Gastroenterologic Phycomycosis
Genetic Epidermolysis bullosa, facioscapulohumeral muscular dystrophy, ichthyosis, incontinentia pigmenti, xeroderma pigmentosum
Hematologic Henoch-Schönlein purpura
Iatrogenic Radial keratotomy
Infectious Disease Acanthamoeba, adenovirus, aspergillus fumigatus, bacillus cereus, balamuthia mandrillaris, brucellosis, candida, canine herpesvirus, congenital syphilis, conjunctivitis, corynebacterium diphtheriae, crab louse, dendritic ulcer, enterobacteria, enterovirus, feline viral rhinotracheitis, fungal keratitis, fusarium, haemophilus influenzae, herpes simplex keratitis, herpes simplex virus infection, herpes zoster, herpesviridae, herpetic keratitis, late congenital syphilitic oculopathy, lepromatous leprosy, listeria, Lyme disease, mansonella ozzardi, measles, microsporidiosis, moraxella, mycobacterium boenickei, mycobacterium brisbanense, mycobacterium houstonense, mycobacterium neworleansense, mycobacterium, naegleria infection, neisseria gonorrhea, nocardiosis, onchocerciasis, orthopoxvirus, parechovirus, plesiomonas shigelloides, pseudomonas aeruginosa, psittacosis, scedosporium apiospermum, serratia marcescens, shigella, smallpox, staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, syphilis, trachoma, vaccinia, varicella-zoster virus
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous No underlying causes

Causes in Alphabetical Order

The unnamed parameter 2= is no longer supported. Please see the documentation for {{columns-list}}.
3

Symptoms

The symptoms are often very similar to those of conjunctivitis, an inflammation of the conjunctiva, and photophobia. The eye turns very red and there may be sensitivity to light, and the eye may feel uncomfortable. In the later stages of more severe cases, there can be strong pain, loss of vision/blurriness, and pus may form.

Diagnosis

Effective diagnosis is important in detecting this condition and subsequent treatment as keratitis is sometimes mistaken for an allergic conjunctivitis.

Treatment

  • Treatment depends on the cause of the keratitis.
  • Microbial keratitis should be managed as bacterial keratitis until proven otherwise.
  • Steroids are indicated in the management of keratitis to reduce inflammation that may damage the eye.

Antimicrobial regimens

Bacterial Keratitis[1]

  • 1. Causative pathogens
  • Pseudomonas aeruginosa
  • Staphylococcus epidermidis
  • Staphylococcus aureus
  • Streptococcus pneumoniae
  • Serratia spp.
  • Hemophilus spp.
  • Moraxella spp.
  • Neisseria gonorrhea
  • Corynebacterium diphtheriae
  • Listeria spp.
  • Shigella spp.
  • Nocardia spp.
  • Mycobacterium spp.
  • 2. Empiric antimicrobial therapy
  • Preferred regimen (1): Ciprofloxacin 0.3% ophthalmic ointment q15min for 6 hours then q30min for the remainder of day 1 then q1h on day 2, then q4h on days 3-14
  • Preferred regimen (2): Ofloxacin 0.3% ophthalmic ointment q2h for 2-3 weeks
  • Preferred regimen (3): Levofloxacin 1.5% ophthalmic ointment q2h for 2-3 weeks
  • Preferred regimen (4): Moxifloxacin 0.5% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Preferred regimen (5): Gatifloxacin 0.3% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Preferred regimen (6): Cefazolin 5% q30min to q1h on day 1 then q2h on day 2 then q4h on days 3-14 AND Tobramycin 5% ophthalmic ointment q1h on day 1 then q2h on day 2 then q4h on days 3-14 OR Gentamicin 1.5% ophthalmic ointment q30min to q1h on day 1 then q1h on day 2 then q4h on days 3-14)
  • Alternative regimen (1), unresponsive keratitis: Vancomycin 5% q30 min on day 1 then q2h on day 2 then q4h on days 3-14 AND Amikacin 5% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Alternative regimen (2): Erythromycin 0.5% ophthalmic ointment qhs for 1 week AND (Amikacin 5% AND/OR Vancomycin 5% q30 min on day 1 then q2h on day 2 then q4h on days 3-14)
  • Note (1) : Subconjunctival antibiotics may be helpful where there is imminent scleral spread or perforation or in cases where adherence to the treatment regimen is questionable.
  • Note (2) : Systemic therapy is necessary for suspected gonococcal infection.
  • 3. Pathogen-directed antimicrobial therapy
  • 3.1 Non-streptococcal gram-positive bacteria
  • Preferred regimen (1): Moxifloxacin 0.5% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Preferred regimen (2): Gatifloxacin 0.3% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Preferred regimen (3): Ciprofloxacin 0.3% ophthalmic ointment q15min for 6 hours then q30min for the remainder of day 1 then q1h on day 2, then q4h on days 3-14
  • Preferred regimen (4): Ofloxacin 0.3% ophthalmic ointment q2h for 2-3 weeks
  • Preferred regimen (5): Levofloxacin 1.5% ophthalmic ointment q2h for 2-3 weeks
  • Preferred regimen (6): Cefazolin 5% q30min to q1h on day 1 then q1h on day 2 then q4h on days 3-14 AND Tobramycin 5% ophthalmic ointment q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • 3.2 Streptococcus pneumoniae
  • Preferred regimen (1): Moxifloxacin 0.5% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Preferred regimen (2): Gatifloxacin 0.3% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Preferred regimen (3): Ciprofloxacin 0.3% ophthalmic ointment q15min for 6 hours then q30min for the remainder of day 1 then q1h on day 2, then q4h on days 3-14
  • Preferred regimen (4): Ofloxacin 0.3% ophthalmic ointment q2h for 2-3 weeks
  • Preferred regimen (5): Levofloxacin 1.5% ophthalmic ointment q2h for 2-3 weeks
  • Preferred regimen (6): Cefazolin 5% q30min to q1h on day 1 then q1h on day 2 then q4h on days 3-14 AND Tobramycin 5% ophthalmic ointment q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Alternative regimen (unresponsive keratitis): Vancomycin 5% q30 min on day 1 then q2h on day 2 then q4h on days 3-14 AND Amikacin 5% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • 3.3 Nocardia spp.
  • Preferred regimen (1): Vancomycin 5% q30 min on day 1 then q2h on day 2 then q4h on days 3-14 AND Amikacin 5% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Preferred regimen (2): Erythromycin 0.5% ophthalmic ointment qhs for 1 week AND (Amikacin 5% AND/OR Vancomycin 5% q30 min on day 1 then q2h on day 2 then q4h on days 3-14)
  • 3.4 Gram-negative bacteria
  • Preferred regimen (1): Moxifloxacin 0.5% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Preferred regimen (2): Gatifloxacin 0.3% q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • Preferred regimen (3): Ciprofloxacin 0.3% ophthalmic ointment q15min for 6 hours then q30min for the remainder of day 1 then q1h on day 2, then q4h on days 3-14
  • Preferred regimen (4): Ofloxacin 0.3% ophthalmic ointment q2h for 2-3 weeks
  • Preferred regimen (5): Levofloxacin 1.5% ophthalmic ointment q2h for 2-3 weeks
  • Preferred regimen (6): Cefazolin 5% q30min to q1h on day 1 then q1h on day 2 then q4h on days 3-14 AND Tobramycin 5% ophthalmic ointment q1h on day 1 then q2h on day 2 then q4h on days 3-14
  • 3.5 Anaerobes
  • Preferred regimen (1): Ciprofloxacin 0.3% ophthalmic ointment q15min for 6 hours then q30min for the remainder of day 1 then q1h on day 2, then q4h on days 3-14
  • Preferred regimen (2): Ofloxacin 0.3% ophthalmic ointment q2h for 2-3 weeks
  • Preferred regimen (3): Levofloxacin 1.5% ophthalmic ointment q2h for 2-3 weeks

Fungal (mycotic) Keratitis[2]

  • 1. Causative Pathogens.
  • Candida spp.
  • Fusarium spp.
  • Aspergillus spp.
  • Curvularia spp.
  • 2. Empiric antimicrobial therapy
  • Preferred regimen (1): Natamycin 5% ophthalmic suspension q30min to q1h for 2-3 weeks
  • Preferred regimen (2): Fluconazole 1% ophthalmic suspension q1h for 2-3 weeks
  • Preferred regimen (3): Natamycin 5% ophthalmic suspension q30min to q1h for 2-3 weeks AND Fluconazole 1% ophthalmic suspension q1h for 2-3 weeks
  • Alternative regimen (1), unresponsive: Amphotericin B 0.15-0.25% prepared in distilled water q15min-q30min on day 1-2 then q1h to q2h for 2-3 weeks
  • Alternative regimen (2), unresponsive: Natamycin 5% ophthalmic suspension q30min to q1h for 2-3 weeks AND Amphotericin B 0.15-0.25% prepared in distilled water q15min-q30min on day 1-2 then q1h to q2h for 2-3 weeks
  • 3. Special considerations
  • Immunocompromised status, spreading ulcer, impending perforation, true perforation
  • Preferred regimen (1): Natamycin 5% ophthalmic suspension q30min to q1h for 2-3 weeks AND Fluconazole 1% ophthalmic suspension q1h for 2-3 weeks AND (Ketoconazole IV 200-400 mg q12h for 2-3 weeks OR Fluconazole IV 200 mg q12h for 2-3 weeks
  • Preferred regimen (2): Natamycin 5% ophthalmic suspension q30min to q1h for 2-3 weeks AND Amphotericin B 0.15-0.25% prepared in distilled water q15min-q30min on day 1-2 then q1h to q2h for 2-3 weeks AND (Ketoconazole IV 200-400 mg q12h for 2-3 weeks OR Fluconazole IV 200 mg q12h for 2-3 weeks
  • Note: Bacterial superinfection must be treated using Ciprofloxacin 0.3% ophthalmic ointment q15min for 6 hours then q30min for the remainder of day 1 then q1h on day 2, then q4h on days 3-14 OR (Cefazolin 5% q30min to q1h on day 1 then q1h on day 2 then q4h on days 3-14 AND Tobramycin 5% ophthalmic ointment q1h on day 1 then q2h on day 2 then q4h on days 3-14)

Protozoal Keratitis[2][3]

  • 1. Causative pathogens
  • Acanthamoeba spp.
  • Microsporidia spp.
  • 2. Empiric antimicrobial therapy

Viral Keratitis[2]

  • 1. Causative pathogens
  • Herpes simplex virus (HSV)
  • 2. Empiric antimicrobial therapy
  • Preferred regimen (1): Acyclovir 3% ophthalmic ointment q5h for 2-3 weeks AND Homatropine 2% ophthalmic solution bid for 2-3 weeks
  • Preferred regimen (2): Idoxuridine 0.1% ophthalmic solution q1h in daytime and 0.5% ophthalmic ointment qhs for 1 week then 0.1% ophthalmic solution q2h in daytime and 0.5% ophthalmic ointment qhs for 2-3 weeks AND Homatropine 2% ophthalmic solution bid for 2-3 weeks

Contraindicated medications

Epithelial herpes simplex keratitis is considered an absolute contraindication to the use of the following medications:

References

  1. "= bacterial keratitis ppp 2013".
  2. 2.0 2.1 2.2 Thomas PA, Geraldine P (2007). "Infectious keratitis". Curr Opin Infect Dis. 20 (2): 129–41. doi:10.1097/QCO.0b013e328017f878. PMID 17496570.
  3. Dart JK, Saw VP, Kilvington S (2009). "Acanthamoeba keratitis: diagnosis and treatment update 2009". Am J Ophthalmol. 148 (4): 487–499.e2. doi:10.1016/j.ajo.2009.06.009. PMID 19660733.

Related Chapters

External Links



Template:WikiDoc Sources